No Data
Goldman Sachs: Oral weight loss drugs will be one of the most promising new medications in recent years!
Goldman Sachs predicts that by 2030, oral weight loss drugs will account for 24% of the total weight loss drug market, and Eli Lilly and Co will lead this segment with its orforglipron. Next, pay close attention to the third-quarter results of the ATTAIN-1 trial announced by Eli Lilly, which will be the first reading of orforglipron in the field of obesity and the most important next catalyst for the oral obesity drug market.
Alexandria Ocasio-Cortez Asks,'How Much Did Majorie Taylor Greene Make When She Bought The Dip?'
U.S. stocks closed mixed: the three major Indexes showed different trends as investors focused on Technology stock Earnings Reports.
① Most China Concept Stocks rose, with the Nasdaq China Golden Dragon Index up 0.68%; ② IBM announced a 150 billion dollar investment plan; ③ Sony Group is reportedly considering splitting its Semiconductors business; ④ NXP Semiconductors Q1 revenue was 2.84 billion dollars, higher than market expectations.
OpenAI Integrates Shopping Features Into ChatGPT
IWF ETF Declines 0.1%
Nasdaq, S&P, Dow Observed Limited Moves as Markets Closed Near Even With Earnings on Deck
Silverbat : Luckily sold over 119.25
面如冠玉的惠特克 : I'm half out of 119.38
Rick Esco OP 面如冠玉的惠特克 : Safe Rewarding Move
IM TRADER : Sold half of the position at 118.5. Sold too early